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Abstract
The combination of sarcopenia, age-related loss of muscle strength and mass, and obesity has been recognized as a new
category of obesity among the elderly. Given that leptin has been hypothesized to be involved in the pathogenesis of
sarcopenic obesity, we investigated the relationship between plasma leptin levels and thigh muscle sarcopenia and visceral
obesity. Thigh muscle cross-sectional area (CSA) and visceral fat area were measured using computed tomography as
indices for muscle mass and visceral fat, respectively, in 782 middle-aged to elderly subjects (303 men and 479 women),
participating in a medical check-up program. Visceral obesity was defined as visceral fat area .100 cm
2, and sarcopenia was
defined as , (one standard deviation 2 mean of thigh muscle CSA/body weight of young subjects [aged ,50
years]). Thigh muscle CSA was significantly and negatively associated with plasma levels of leptin in both men (b=-0.28,
p,0.0001) and women (b=-0.20, p,0.0001), even after correcting for other confounding parameters, including age, body
weight, body height, visceral fat area, blood pressure, homeostatic model assessment index, and high sensitive C reactive
protein. Subjects were divided into four groups based on presence or absence of sarcopenia or visceral obesity. Plasma
levels of leptin were higher in subjects with sarcopenic visceral obesity than in those with either sarcopenia or visceral
obesity alone. These findings indicate that sarcopenic visceral obesity is a more advanced, and suggest that leptin may link
visceral obesity and sarcopenia.
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Introduction
Obesity, particularly visceral obesity, is a global pandemic
known to be related to numerous pathological conditions,
including metabolic syndrome, diabetes, hypertension, and
cardiovascular disease [1–3]. Sarcopenia, which is the age-related
loss of muscle mass, is another concern in today’s aging society [4].
In particular, sarcopenia in the legs leads to functional
impairments such as postural instability, falling, and frailty,
eventually culminating in loss of independence and death [5].
Recent studies have turned attention to sarcopenic-obesity, a
deadly combination of the above two conditions which synergis-
tically deteriorates metabolic disorders as well as functional
abnormalities [1–3]. Prevalence of sarcopenic-obesity is increasing
in industrialized countries due to increased prevalence of obesity
itself and sarcopenia in obese subjects [1–3,6]. Determining the
underlying mechanisms linking sarcopenia and obesity is therefore
crucial to enacting effective intervention protocols.
Adipocyte-myocyte crosstalk via adipokines is believed to
underlie the pathophysiology of obesity-related disorders [7].
Leptin is released from adipocytes and exerts a range of
pathological and physiological actions on a number of organs,
including skeletal muscle [8]. Specifically, leptin acts on skeletal
muscles to stimulate lipolysis and insulin sensitivity [9]. Serum
levels of leptin increase with fat accumulation [8–10]. Although its
central effect decreases in this state, leptin maintains its peripheral
effect, subsequently leading to stimulation of the sympathetic
nervous system and platelet aggregation, effects which may
underlie the connection between obesity and cardiovascular
diseases such as hypertension [11] and atherosclerosis [10].
Leptin receptors have been shown to be down-regulated by
leptin itself or via insulin resistance [10]. Since skeletal muscle is
the major site of glucose consumption, presence of sarcopenia is
another risk factor in developing insulin resistance [1–3].
Further, leptin receptor numbers may be reduced along with
muscle mass in patients with sarcopenia, possibly resulting in
further increases in plasma leptin concentration. These findings
suggest that leptin may play a greater role in sarcopenic obesity
than in simple obesity. However, studies evaluating the
relationship between sarcopenia and circulating leptin levels
have thus far drawn inconclusive results due to a small patient
population [12–14].
Here, we conducted a cross-sectional study to investigate
relationships between plasma leptin levels and sarcopenia and
obesity in 782 middle-aged to elderly subjects participating in a
medical check-up program in Japan.
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Study subjects
Subjects were independent middle-aged to elderly persons
recruited from among consecutive visitors to the Anti-Aging
Center at Ehime University Hospital from March 2006 to March
2009. They attended the voluntary medical check-up program,
‘‘Anti-Aging Doc,’’ a program provided to general residents of
Ehime Prefecture, Japan, specifically designed to evaluate aging-
related disorders, including atherosclerosis, cardiovascular disease,
physical function, and mild cognitive impairment [15,16]. Of the
844 consecutive patients initially approached, a total of 782 who
agreed with the study aims and protocols, gave written consent to
all procedures, and were free of any history of symptomatic
cardiovascular events including peripheral arterial diseases, stroke,
coronary heart disease, and congestive heart failure were analyzed.
All participants were physically independent in their daily lives.
The series of studies to which the present study belongs was
approved by the Ethics Committee of Ehime University Graduate
School of Medicine.
Measurement of femoral muscle cross-sectional area and
visceral fat area
Femoral muscle cross-sectional area (CSA) was measured using
computed tomography (CT; LightSpeed VCT; GE Healthcare,
Tokyo, Japan) at the mid-thigh, measured as the midpoint from
the inguinal crease to the proximal pole of the patella [16]. The
muscle CSA (cm
2) was computed using an attenuation range of 0
to 100 Hounsfield units. Visceral fat area was measured using CT
at the level of the umbilicus, with attenuation ranging from 150 to
50 Hounsfield units. CT images were obtained with a minimal
slice width of 5 mm and analyzed using OsiriX software (OsiriX
Foundation, Geneva, Switzerland) (Fig. 1) [17]. All images were
analyzed by a single investigator under blinded conditions
(O.M.).
Figure 1. Thigh muscle CT (top) at the mid-thigh level and
abdominal CT (bottom) at umbilicus level. Thigh muscle cross-
sectional area (CAS) and visceral fat area (Vis) were obtained.
doi:10.1371/journal.pone.0024633.g001
Figure 2. Scatter plots between thigh muscle cross-sectional
area and body weight (top) and body height (bottom).N: men,
#: women.
doi:10.1371/journal.pone.0024633.g002
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sarcopenia
Visceral obesity was defined as a visceral fat area .100 cm
2 in
both men and women, in accordance with the Japanese criterion
defining metabolic syndrome [18]. The category of ‘‘overweight,’’
defined as having a BMI.25 kg/m
2, was also evaluated as an
obesity index. Since thigh muscle CSA showed a strong association
with body weight (BW) (Fig. 2), thigh muscle CSA was corrected
by body weight (CSA/BW) as a sarcopenic index of BW burden
thigh muscle mass. Sarcopenia was defined in both men and
women as having CSA/BW within one standard deviation value
of the CSA/BW distribution in subjects aged ,50 years among
study participants [8,19].
Biochemical determination
To determine biochemical variables, blood samples were
obtained from each subject after fasting overnight for at least
11 h. jePlasma concentrations of leptin were determined using a
commercially available RIA kit (Leptin HL-81K; Linco Research,
Inc., St. Charles, MO, USA) [20]. Coefficients of variation in our
inter- and intra-assay were 7.2% and 4.1%, respectively.
Statistical analysis
Values are expressed as the mean 6 standard deviation unless
otherwise specified. Subjects were divided into three groups
according to their thigh muscle CSA and abdominal visceral fat
area. Since body composition profiles differ between men and
women, tertiles were obtained separately for both sexes. Factors
independently associated with plasma levels of leptin were assessed
using multiple regression analysis with two models, model 1 with
anthropometric parameters and model 2 with further parameters
possibly related to leptin levels. Plasma levels of leptin in all tertiles
of visceral fat area and thigh muscle CSA were also evaluated via
multiple regression analysis with age, BH, and BW.
Table 1. Clinical characteristics of study population.
Men Women p
N 303 479
Age, years 67.968.5 66.368.2 0.0045
Body height, cm 164.965.9 152.265.3 , .0001
Body weight, kg 64.568.8 52.767.8 , .0001
Body mass index, kg/m
2 23.762.9 22.863.2 , .0001
Waist, cm 86.068.0 82.569.2 , .0001
Hip, cm 92.565.4 90.165.7 , .0001
Waist/hip ratio 0.9360.05 0.9160.07 0.0007
Visceral fat area, cm
2 128.4664.8 87.4651.6 , .0001
Thigh muscle CSA, cm
2 133.5617.7 96.1613.3 , .0001
Thigh muscle CSA/BW, cm
2/kg 2.160.2 1.860.2 , .0001
Systolic blood pressure, mmHg 138.1619.3 136.1619.7 0.16
Diastolic blood pressure, mmHg 79.7611.4 76.9611.1 0.0013
Heart rate, beats/min 64.7611.3 67.2610.1 0.001
Total cholesterol, mg/dl 207.7632.5 225.6635.7 , .0001
HDL cholesterol, mg/dl 61.5617.7 73.0618.4 , 0.001
Triglyceride, mg/dl 111.8657.7 101.3655.0 0.0064
Fasting glucose, mg/dl 107.4618.5 100.5615.0 , .0001
Insulin, mU/ml 5.9863.72 5.4963.94 0.069
HbA1c, % 5.660.7 5.560.6 0.062
HOMA-R 1.661.2 1.461.2 0.0077
hs-CRP, mg/dl 0.1160.12 0.0960.12 0.12
WBCs, /mL5 6 9 8 61564 517761288 , .0001
Medication, n (%)
Hypertension 99 (33) 127 (27) 0.087
Dyslipidemia 46 (15) 117 (24) 0.003
Diabetes 21 (7) 22 (5) 0.17
Smoking, current/past/never
smoker, n
39/187/77 11/25/443 , .0001
CSA, cross sectional area; BW, body weight; HDL, high density lipoprotein;
HbA1c, hemoglobin A1c; HOMA, homeostatic model assessment; hs-CRP, high-
sensitivity C-reactive protein; WBCs, white blood cells, P indicates p values
between men and women.
doi:10.1371/journal.pone.0024633.t001
Figure 3. Plasma leptin levels in tertiles of visceral fat area and
thigh muscle cross-sectional area (CSA). Multiple regression
analysis was performed for plasma leptin concentration with the
following parameters in each sex: age, body weight, body height,
tertiles of visceral fat area, tertiles of thigh muscle CSA, and interaction
and interaction between visceral fat and thigh muscle tertiles. All values
are mean values. Men: Visceral fat area tertile: F=5.1, p=0.007. Thigh
muscle CSA tertile: F=8.5, p=0.0003. Interaction: F=1.5, p=0.33.
Women: Visceral fat area tertile: F=7.6, p=0.0006. Thigh muscle CSA
tertile: F=5.2, p=0.006. Interaction: F=1.1, p=0.34.
doi:10.1371/journal.pone.0024633.g003
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and absence of visceral obesity and thigh muscle sarcopenia. The
four groups—established base on being overweight or not and
presence or absence of thigh muscle sarcopenia—were also
evaluated.
Differences in numeric variables among groups were assessed
using analysis of variance (ANOVA) followed by Bonferroni
correction for multiple comparison test, and differences in
frequency were assessed using the chi-squared test. All analyses
were conducted using commercially available statistical software
(JMP ver. 8.0; SAS Institute, Cary, NC, USA), with p,0.05
considered statistically significant.
Results
Plasma leptin with visceral fat area and thigh muscle CSA
Clinical characteristics of the study population are shown in
Table 1. Both thigh muscle CSA and abdominal visceral fat area
were found to be significantly related to BW (r=0.80, p,.0001,
and r=0.70, p,.0001, respectively) (Fig. 2). Thigh muscle CSA
was also significantly related to body height (BH) (r=0.70,
p,0.0001)
Plasma levels of leptin in the tertiles of visceral fat area and thigh
muscle CSA after correction for age, BH and BW are shown in
Figure 3. In both men and women, plasma levels of leptin were
significantly and positively related to visceral fat area and inversely
related to thigh muscle CSA.
Multiple regression analysis for plasma levels of leptin
We conducted multiple regression analyses to investigate
whether or not thigh muscle CSA is independently associated
with plasma levels of leptin (Table 2). After correction for
possible confounding parameters, including age, BH, BW,
abdominal visceral fat area, systolic and diastolic blood pressure
(BP), levels of total cholesterol, high-density lipoprotein choles-
terol, triglyceride, HbA1c, Homeostatic Model Assessment as an
index of insulin resistance (HOMA-R), hs-CRP, and white blood
cell count, thigh muscle CSA was found to be independently,
significantly, and negatively related to plasma leptin levels in both
men and women.
Plasma leptin in sarcopenic visceral obesity
To explore the combined effect of sarcopenia and visceral
obesity on plasma levels of leptin, four groups based on presence
or absence of either or both thigh muscle sarcopenia and visceral
obesity were compared. After adjustment for age and BW, levels of
plasma leptin were found to be highest in both men and women
among subjects with sarcopenic visceral obesity followed by simple
obesity (Table 3, 4, and Fig. 4).
Tables 3 and 4 also summarize metabolic and inflammatory
parameters in the four groups. We noted no differences in blood
pressure or total cholesterol among in men or women in any
groups. However, insulin resistance parameters—including fasting
insulin and HOMA-R—and numbers of WBCs were significantly
increased among patients with sarcopenic visceral obesity
compared with normal men and women.
Plasma leptin in sarcopenic overweight individuals
Plasma levels of leptin in normal, sarcopenic, overweight, and
sarcopenic overweight groups are depicted in Fig 5. Similar to
findings in individuals with sarcopenic visceral obesity, plasma
leptin levels after adjustment for age and BW were highest in both
male and female sarcopenic overweight subjects compared with all
other three groups.
Table 2. Multiple regression analysis for plasma leptin concentration.
Model 1 Model 2
Men Women Men Women
b p b p b P b P
Age, years -0.06 0.25 0.01 0.79 0 0.98 -0.01 0.82
Body height, cm -0.25 ,.0001 -0.17 0.0002 -0.15 0.005 -0.13 0.002
Body weight, kg 0.71 ,.0001 0.54 ,.0001 0.55 ,.0001 0.47 ,.0001
Visceral fat area, cm
2 0.28 ,.0001 0.28 ,.0001 0.23 0.0004 0.23 ,.0001
Thigh muscle CSA -0.33 ,.0001 -0.2 ,.0001 -0.27 ,.0001 -0.2 ,.0001
Systolic BP, mmHg -0.1 0.07 0.01 0.88
Diastolic BP, mmHg 0.05 0.34 0 0.94
Total cholesterol, mg/dl 0.07 0.09 0.02 0.7
HDL cholesterol, mg/dl 0.08 0.1 0.01 0.77
Triglyceride, mg/dl -0.07 0.14 -0.01 0.75
HbA1c, % -0.1 0.042 -0.04 0.37
HOMA-R 0.39 ,.0001 0.25 ,.0001
hs-CRP 0.01 0.71 0.02 0.54
WBCs 0.02 0.58 0.04 0.23
Antihypertensive drugs, yes=1 -0.01 0.9 -0.01 0.74
Antidislipidemic drug use, yes=1 0.09 0.037 0.03 0.46
Diabetic medication, yes=1 -0.07 0.14 -0.07 0.12
CSA, cross sectional area; BW, body weight; HDL, high density lipoprotein; HbA1c, hemoglobin A1c; HOMA, homeostatic model assessment; hs-CRP, high-sensitivity C-
reactive protein; WBCs, white blood cells.
doi:10.1371/journal.pone.0024633.t002
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Here, we found that plasma leptin levels were significantly,
independently, and negatively related to thigh muscle CSA in
middle-aged to elderly men and women. Further, in both men and
women, leptin levels were found to be higher in subjects with both
thigh muscle sarcopenia and visceral obesity or being overweight
than in those with only one abnormality. These findings suggest
that plasma leptin level may be associated with not only visceral fat
but also skeletal muscle mass.
Previous studies investigating the association between leptin and
sarcopenia have been inconclusive. Go ´mez et al. [12] noted a
positive relationship between serum levels of leptin and fat-free
mass in both men and women. However, after correction for other
confounding parameters, the authors ultimately concluded that
free-fat mass did not contribute to leptin levels [12]. Hubbard et al.
[13] reported low leptin levels in frail elderly subjects with reduced
mid-arm muscle area, and they speculated it was due to low body
fat [13]. In contrast, in their study involving 45 healthy elderly
subjects, Waters et al. [14] reported a negative correlation between
appendicular skeletal muscle mass as measured using a dual
energy X-ray absorptiometer and leptin levels after correction with
body fat. We confirmed these authors’ findings in a much larger
population using the more specifically quantified thigh muscle
CSA.
We further observed that subjects with sarcopenic visceral
obesity had higher leptin levels than in any other groups, including
visceral obese subjects without sarcopenia, findings which ran
counter to observations by Waters et al. [14]. After correction for
fat mass, these authors noted higher concentrations of leptin
among subjects with sarcopenia than those with sarcopenic obesity
[14]. The differing results between our study and that of Waters et
al. may be due to differing definitions of sarcopenia and obesity.
Waters et al. used appendicular muscle mass corrected by BH
2
(m
2) as an index for sarcopenia and defined sarcopenia as two SD
below the sex-specific mean values for young adults aged 18-40
years. In the present study, we used thigh muscle CSA corrected
by BW, since thigh muscle CSA showed higher associations with
BW than BH
2 both in men (r=0.73 vs. r=0.35, p,0.0001) and
women (r=0.66 vs. r=0.27, p,0.0001). Further we defined
visceral obesity as visceral fat area .100 cm
2, in accordance with
the Japanese guidelines for metabolic syndrome [19].
Since visceral fat area was higher in sarcopenic obesity group
than single obesity group after correction for age, the difference in
Table 3. Clinical characteristics of subjects with thigh muscle sarcopenia, visceral obesity and sarcopenic visceral obesity in men.
Normal Sarcopenia Visceral obesity
Sarcopenic
visceral obesity P
N 78 19 133 73
Age, years 67.968.1 73.065.0* 65.768.2 70.569.3*
{ ,.0001
Body Height
a, cm 165.165.4 166.365.4 163.465.4 166.965.4* 0.0002
Body Weight
a, kg 57.667.0 59.767.1 65.767.2
*{ 71.067.1
*{{ ,.0001
Body mass index
a,k g / m
2 21.162.3 21.662.3 24.662.3
*{ 25.562.3
*{{ ,.0001
Waist/hip ratio
a 0.8860.04 0.9160.04 0.9460.05
*{ 0.9660.04
*{ ,.0001
Visceral fat area
a,c m
2 52.8639.8 65.0640.3 154.2640.5
*{ 178.6640.3
*{{ ,.0001
Thigh muscle CSA
a,c m
2 127.9614.0 113.2614.2* 141.0614.2*
{ 131.1614.2
{{ ,.0001
Thigh muscle CSA/BW
a,c m
2/kg 2.2260.13 1.8960.13* 2.1560.13*
{ 1.8560.13*
{ ,.0001
Leptin
a, mg/L 1.962.3 2.662.3* 4.362.3*
{ 5.762.3
*{{ ,.0001
Systolic blood pressure
b, mmHg 129.8620.3 132.1618.7 142.9618.5* 139.7620.5* 0.0001
Diastolic blood pressure
b, mmHg 75.1612.4 76.2611.3 82.4611.5* 80.4612.0* 0.0004
Total cholesterol
b, mg/dl (mmol/L) 203.6636.1 (5.2760.97) 195.1632.3 (5.0560.87) 211.9633.0 (5.4960.92) 207.4635.6 (5.3760.94) 0.15
HDL cholesterol
b,mg/ml (mmol/L) 65.3618.4 60.9616.5 59.2616.9
* 61.6618.2 0.12
(1.6960.44) (1.5860.44) (1.5360.46
*) (1.6060.51)
Triglyceride
b, mg/dl (mmol/L) 86.9660.0 95.2653.8 125.5654.8
* 117.8659.4
* 0.0001
(0.9860.71) (1.0860.61) (1.4260.58
*) (1.3360.77
*)
Fasting lucose
b, mg/dl (mmol/L) 102.4620.3 113.9618.2 106.5618.6 112.7619.9
* 0.0096
(5.6861.15) (6.3261.05) (5.9161.04) (6.2561.11
*)
Insulin
b, mU/mL
(pmol/L)
5.0763.60 50.963.27 61.663.33 6.8563.56
* 0.036
(35.4624.7) (35.4624.4) (43.1624.2) (47.9623.9
*)
HbA1c
b,% 5 . 4 60.7 5.760.7 5.660.7* 5.960.8
*{ 0.0009
HOMA-R
b 1.3061.24 1.3961.13 1.6561.15 1.9961.20
* 0.014
hs-CRP
b, mg/dl 0.1460.34 0.1060.31 0.1560.31 0.1560.34 0.92
WBC
b,/ml 525561713 601761574 564861568 611561700
* 0.024
CSA, cross sectional area; BW, body weight; HDL, high density lipoprotein; HbA1c, hemoglobin A1c, HOMA, homeostatic model assessment; hs-CRP, high-sensitivity C-
reactive protein; WBC, white blood cell.
a: corrected for age,
b: corrected for age and body weight.
doi:10.1371/journal.pone.0024633.t003
Leptin in Sarcopenic Visceral Obesity
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24633plasma leptin between the two groups could be influenced by
visceral fat area itself rather than thigh muscle CSA. Accordingly
we performed further adjustment with BW. After adjustment,
there was no significant difference in visceral fat area between the
two groups, while plasma leptin was significantly higher in
sarcopenic obesity than single obesity group. These findings
together with the result of multiple regression analyses indicate
that thigh muscle CSA negatively related to plasma leptin levels
independently of visceral fat area. Further, in a separate analysis
we evaluated the effect of BMI-defined overweight condition on
plasma levels of leptin. After correction for age and BW, both
male and female sarcopenic overweight individuals (BMI.25 kg/
m
2) had the highest plasma leptin levels of all groups measured.
These findings indicate that the effect of sarcopenia on plasma
levels of leptin is not only independent of visceral fat area but also
BMI.
Determining the mechanisms behind the negative association
between thigh muscle CSA and plasma leptin is beyond the scope
of the present study. However, leptin is known to stimulate
inflammation [7–10], and serum leptin levels have also been
shown to be negatively correlated with IGF-1 levels and
testosterone [21]. Given that these factors are known to play roles
in development of sarcopenia [1–3], leptin may also play a
causative role in development of sarcopenia. Exogenous leptin has
also been shown to reduce protein synthesis in myocytes [22]. In
contrast, a recent study demonstrated that leptin treatment
significantly increased hindlimb muscle mass and extensor
digitorum longus fiber size in aged mice [23]. Given that obesity
is associated with reduced number and function of leptin receptors
in leg muscle [24], these present and previous findings suggest that
impaired action of leptin in skeletal muscle may also induce
development of sarcopenia.
Several limitations to our study warrant mention. The cross-
sectional nature of our research hampered to determine that
obesity and sarcopenia affect plasma leptin levels. In addition, our
study subjects were free from any symptomatic cardiovascular
diseases, and few had BMI.30; as such, our findings may not be
easily extrapolated to different ethnicities, younger generations, or
subjects with more severe obesity. A longitudinal study involving a
more divergent population will be necessary to address these
points.
In summary, thigh muscle CSA was negatively associated with
plasma leptin concentration in middle-aged to elderly subjects,
independent of known confounding factors, including age, BW,
Table 4. Clinical characteristics of subjects with thigh muscle sarcopenia, visceral obesity and sarcopenic visceral obesity in
women.
Normal Sarcopenia Visceral obesity
Sarcopenic
visceral obesity P
N 78 19 133 73
Age, years 67.968.1 73.065.0* 65.768.2 70.569.3*
{ ,.0001
Body Height
a, cm 165.165.4 166.365.4 163.465.4 166.965.4* 0.0002
Body Weight
a, kg 57.667.0 59.767.1 65.767.2
*{ 71.067.1
*{{ ,.0001
Body mass index
a,k g / m
2 21.162.3 21.662.3 24.662.3
*{ 25.562.3
*{{ ,.0001
Waist/hip ratio
a 0.8860.04 0.9160.04 0.9460.05
*{ 0.9660.04
*{ ,.0001
Visceral fat area
a,c m
2 52.8639.8 65.0640.3 154.2640.5
*{ 178.6640.3
*{{ ,.0001
Thigh muscle CSA
a,c m
2 127.9614.0 113.2614.2* 141.0614.2*
{ 131.1614.2
{{ ,.0001
Thigh muscle CSA/BW
a,c m
2/kg 2.2260.13 1.8960.13* 2.1560.13*
{ 1.8560.13*
{ ,.0001
Leptin
a, mg/L 1.962.3 2.662.3* 4.362.3*
{ 5.762.3
*{{ ,.0001
Systolic blood pressure
b, mmHg 129.8620.3 132.1618.7 142.9618.5* 139.7620.5* 0.0001
Diastolic blood pressure
b, mmHg 75.1612.4 76.2611.3 82.4611.5* 80.4612.0* 0.0004
Total cholesterol
b, mg/dl (mmol/L) 203.6636.1 (5.2760.97) 195.1632.3 (5.0560.87) 211.9633.0 (5.4960.92) 207.4635.6 (5.3760.94) 0.15
HDL cholesterol
b,mg/ml (mmol/L) 65.3618.4 60.9616.5 59.2616.9
* 61.6618.2 0.12
(1.6960.44) (1.5860.44) (1.5360.46
*) (1.6060.51)
Triglyceride
b, mg/dl (mmol/L) 86.9660.0 95.2653.8 125.5654.8
* 117.8659.4
* 0.0001
(0.9860.71) (1.0860.61) (1.4260.58
*) (1.3360.77
*)
Fasting lucose
b, mg/dl (mmol/L) 102.4620.3 113.9618.2 106.5618.6 112.7619.9
* 0.0096
(5.6861.15) (6.3261.05) (5.9161.04) (6.2561.11
*)
Insulin
b, mU/mL (pmol/L) 5.0763.60 50.963.27 61.663.33 6.8563.56
* 0.036
(35.4624.7) (35.4624.4) (43.1624.2) (47.9623.9
*)
HbA1c
b,% 5 . 4 60.7 5.760.7 5.660.7* 5.960.8
*{ 0.0009
HOMA-R
b 1.3061.24 1.3961.13 1.6561.15 1.9961.20
* 0.014
hs-CRP
b, mg/dl 0.1460.34 0.1060.31 0.1560.31 0.1560.34 0.92
WBC
b,/ml 525561713 601761574 564861568 611561700
* 0.024
CSA, cross sectional area; BW, body weight; HDL, high density lipoprotein; HbA1c, hemoglobin A1c, HOMA, homeostatic model assessment; hs-CRP, high-sensitivity C-
reactive protein; WBC, white blood cell.
a: corrected for age,
b: corrected for age and body weight.
doi:10.1371/journal.pone.0024633.t004
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highlight the importance of sarcopenia in understanding the
pathophysiological aspect of obesity in the elderly population.
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